RohitThummalapalliMD

Oncology • New York, NY

Resident Physician in Internal Medicine

Join to view full profile

Dr. Thummalapalli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thummalapalli's full profile

Already have an account?

Office
160 East 53rd Street
New York, NY 10022

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 2018 - 2021
Harvard Medical SchoolClass of 2017

Certifications & Licensure

NY State Medical License 2021 - 2026
NJ State Medical License 2024 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.
Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib
Journal of Thoracic Oncology. 2024-09-10
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas
Medrxiv. 2024-06-11

Journal Articles

Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous Retroviruses
Scott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature